Daily Anesthesiology Research Analysis
Analyzed 24 papers and selected 3 impactful papers.
Summary
Analyzed 24 papers and selected 3 impactful articles.
Selected Articles
1. Aquaporin-4: A Predictor and Therapeutic Target for Permanent Paraplegia after Endovascular Thoracoabdominal Aortic Aneurysm Repair.
CSF aquaporin-4 levels were markedly elevated in patients who developed permanent paraplegia after endovascular TAAA repair and correlated with spinal cord edema on MRI. In a rodent ischaemic spinal cord injury model, pharmacologic AQP4 inhibition preserved neural elements and prevented paraplegia, positioning AQP4 as both a prognostic biomarker and therapeutic target.
Impact: This study bridges human CSF proteomics with in vivo mechanistic validation, offering a tractable biomarker and target for a devastating perioperative complication. It reframes management of ischaemic spinal cord injury toward biomarker-guided risk stratification and intervention.
Clinical Implications: CSF AQP4 could inform early risk stratification after TAAA repair and guide intensive monitoring or neuroprotective strategies; AQP4 inhibitors warrant evaluation in clinical trials for perioperative spinal cord protection.
Key Findings
- CSF AQP4 was ~4-fold higher in patients with permanent paraplegia (41.8 ± 19.2 ng/mL) versus recovered transient paraplegia or no paraplegia (~10.8 ng/mL).
- CSF AQP4 >15 ng/mL was associated with greater spinal cord edema on T2-weighted MRI.
- In a rodent iSCI model, AQP4 inhibition preserved neurons and glia and prevented ischaemia-induced paraplegia.
Methodological Strengths
- Integrated human CSF proteomics with blinded neurological assessment and imaging correlates.
- Translational validation using an in vivo rodent model targeting AQP4.
Limitations
- Single-cohort sample with modest size (n=37) may limit generalizability.
- Clinical efficacy and safety of AQP4 inhibition remain untested in humans.
Future Directions: Prospective multicenter validation of CSF (and potentially plasma) AQP4 thresholds, development of rapid assays, and early-phase trials of AQP4-targeted neuroprotection in high-risk TAAA patients.
OBJECTIVE: Endovascular thoracoabdominal aortic aneurysm (TAAA) repair can impair spinal cord perfusion, leading to paraplegia. The mechanisms driving this devastating complication are poorly understood. This study aimed to interrogate the cerebrospinal fluid (CSF) proteome in patients after TAAA repair to identify biomarkers that herald permanent paraplegia. It also aimed to investigate a potential therapeutic target identified by proteomics using an in vivo model of ischaemic spinal cord injury (iSCI). METHODS: CSF was collected for proteomic analysis from patients before and following TAAA repair. A differentially expressed protein identified in human paraplegic subjects was subsequently interrogated in a rodent model of iSCI. The protein composition of CSF was analysed using tandem mass tag proteomics. Neurological examinations were carried out by a blinded neurologist and T2 weighted magnetic resonance imaging (MRI) was used to measure spinal cord volume/oedema. A rodent model of iSCI was used to investigate a clinically relevant therapeutic target informed by proteomic findings. RESULTS: CSF analysis was taken from 37 patients, all of whom had aneurysm repair using a custom branched/fenestrated device (median age 73.5 years (range 67 - 78); 27 males, ten females; Crawford classification: six type I, 11 type II, 15 type III, three type IV, and two type V). Five patients remained permanently paraplegic and seven recovered from transient paraplegia. CSF of patients who remained paraplegic contained approximately fourfold more aquaporin-4 (AQP4) (41.8 ± 19.2 ng/mL, n = 5) than those who recovered from paraplegia (10.8 ± 1.3 ng/mL, n = 7; p = .01), or did not develop paraplegia (10.8 ± 1.2 ng/mL, n = 25; p = .004). Permanently paraplegic patients had CSF AQP4 levels > 15 ng/mL and this was associated with greater cord oedema on T2 weighted magnetic resonance imaging (1.77 ± 0.19 vs. 1.03 ± 0.36; p = .03). In a rodent model of iSCI, AQP4 inhibition preserved spinal neurons and glia in the dorsal horn and intermediate zones of white matter (p = .004) and protected against ischaemia induced paraplegia (p < .001). CONCLUSION: The AQP4 level in the CSF of a patient represents a prognostic marker of permanent paraplegia after TAAA repair and highlights a novel therapeutic target. These findings represent a conceptual advance in the management of iSCI.
2. Tubule-Derived GDF15 Limits Renal Transplant Injury by Reprogramming Macrophage Responses.
Human allograft transcriptomics and murine transplantation models identify tubule-derived GDF15 as a protective mediator that limits transplant injury by promoting M2 macrophage polarization. Urinary GDF15 correlates with graft dysfunction, and recombinant GDF15 mitigates injury, implicating ATF4-GDF15 signaling as a therapeutic axis.
Impact: This work uncovers a tubule–macrophage cross-talk mechanism with direct translational relevance, nominating GDF15 as both a biomarker and a therapeutic candidate to reduce IRI and DGF after kidney transplantation.
Clinical Implications: Urinary GDF15 could aid in early identification of grafts at risk for DGF, and recombinant GDF15 or pathway agonism may be explored as peri-transplant immunometabolic therapies to improve outcomes.
Key Findings
- GDF15 is upregulated in renal tubular epithelial cells of human allografts, especially in DGF cases; urinary GDF15 correlates with serum creatinine.
- GDF15 deficiency exacerbates tubular injury and inflammation in murine syngeneic/allogeneic transplant models, while recombinant GDF15 is protective.
- ATF4 regulates GDF15 under renal stress; macrophage depletion confirms macrophage-mediated inflammation drives injury in GDF15-deficient grafts.
Methodological Strengths
- Integrated human transcriptomics with mechanistic murine transplantation models.
- Multi-pronged causality tests including recombinant protein rescue, ATF4 knockout, and macrophage depletion.
Limitations
- Human cohort size and external validation details are not specified in the abstract.
- Translational gaps remain regarding dosing, timing, and safety of recombinant GDF15 in humans.
Future Directions: Prospective studies validating urinary GDF15 as a DGF biomarker, dose-finding and safety trials of recombinant GDF15, and exploration of macrophage-targeted adjuncts in peri-transplant care.
Kidney transplantation remains the gold standard for end-stage renal disease, but ischemia-reperfusion injury (IRI) and delayed graft function (DGF) continue to hinder outcomes. Growth differentiation factor 15 (GDF15), a stress-responsive cytokine from the transforming growth factor-β (TGF-β) superfamily, is upregulated in response to cellular injury and hypoxia. While GDF15 has been studied in acute kidney injury and sepsis, its role in kidney transplantation remains unclear. In this study, we combined transcriptomic analysis of human kidney allografts with murine models to investigate GDF15's role in transplant injury. GDF15 was upregulated in renal tubular epithelial cells, particularly in DGF grafts, and its levels in urine correlated with serum creatinine, indicating a link to graft dysfunction. In syngeneic and allogeneic murine transplant models, GDF15 deficiency worsened tubular injury and inflammation, while recombinant GDF15 (rmGDF15) protected against injury and promoted an anti-inflammatory M2 macrophage phenotype. We also identified activating transcription factor 4 (ATF4) as a key regulator of GDF15 in renal stress, with its knockout reducing GDF15 expression and worsening transplant injury. Macrophage depletion confirmed that macrophage-mediated inflammation was a major factor in GDF15-deficient graft injury. In conclusion, GDF15 regulates kidney transplant injury by modulating macrophage polarization, making it a potential therapeutic target for improving transplant outcomes.
3. Validation of the Diagnosis Procedure Combination Database in Japan for ICU Research: A Multicenter Comparison with the Japanese Intensive care PAtient Database (JIPAD).
In a multicenter validation of 14,070 ICU admissions, Japan’s DPC administrative data showed high accuracy for mortality and most ICU interventions, but under-ascertained comorbidities and noninvasive respiratory support with only moderate agreement for SOFA scores. Results justify DPC use for ICU research while highlighting specific domains requiring correction.
Impact: By establishing variable-level performance against a clinical registry, this study underpins robust ICU health services research using DPC and directs targeted data quality improvements.
Clinical Implications: DPC data are suitable for ICU outcomes and intervention studies, but investigators should supplement comorbidity capture and noninvasive ventilation data, and treat SOFA-based analyses with caution or calibration.
Key Findings
- High sensitivity/specificity (≥80%) for most binary ICU variables including mortality and major interventions.
- Comorbidity coding had >95% specificity but sensitivity <30% for several conditions.
- Invasive ventilation sensitivity 83.3% vs. low sensitivity for NIPPV (5.5%) and HFNC (36.1%); SOFA ICC was 0.61.
Methodological Strengths
- Gold-standard comparison with a national ICU clinical registry (JIPAD).
- Large multicenter sample with comprehensive evaluation of binary and continuous variables.
Limitations
- Analysis restricted to successfully matched records; case ascertainment was not assessed.
- Noninvasive respiratory support under-capture limits analyses of these modalities.
Future Directions: Enhance coding for comorbidities and noninvasive supports, develop calibration algorithms for SOFA, and expand linkage pipelines between DPC and clinical registries.
BACKGROUND: The Diagnosis Procedure Combination (DPC) database is Japan's most widely used administrative inpatient dataset, supporting epidemiological and health services research. While its validity is established for various diagnoses and procedures, accuracy for intensive care unit (ICU) variables has not been directly evaluated using a clinical registry as the gold standard. METHODS: We conducted a multicenter retrospective validation study using four Japanese ICUs. Patient records from the national ICU registry, the Japanese Intensive Care Patients Database (JIPAD), were matched with corresponding DPC data, retaining only successfully matched patients to evaluate coding accuracy rather than case ascertainment. We assessed binary variables (demographics, comorbidities, diagnoses, interventions, ICU admission, mortality) and continuous variables (demographics, Sequential Organ Failure Assessment [SOFA] scores). We calculated sensitivity and specificity for binary variables and intraclass correlation coefficients (ICCs) for continuous variables. RESULTS: We included 14,070 ICU admissions. Most binary variables, including demographics, major diagnostic categories, ICU interventions, and mortality, had high sensitivity and specificity (≥80%). Comorbidity specificity exceeded 95%, but sensitivity was <30% for several diseases. Sensitivity was 83.3% for invasive mechanical ventilation but low for noninvasive positive pressure ventilation (5.5%) and high-flow nasal cannula (36.1%), although specificity was high across respiratory supports (97.3%-99.9%). SOFA scores showed moderate agreement (ICC, 0.61). Sensitivity/specificity were 99.1%/100.0% for in-hospital mortality and 96.2%/99.9% for ICU mortality. CONCLUSIONS: The DPC administrative inpatient database accurately captures most key ICU variables, but comorbidities, noninvasive respiratory support, and SOFA scores require caution. These findings support its use for ICU clinical and epidemiological research in Japan.